A global medical supply leader offering reusable sterilization equipment and disposable patient care products with a resilient distribution network across key international markets.
ICUI presents an attractive turnaround opportunity as it transitions from years of operating losses to profitability while maintaining strong cash generation capabilities that can fund future growth initiatives without excessive dilution; the company's critical role in hospital infection control provides defensive characteristics during economic downturns when discretionary medical spending may be cut; and its global footprint offers diversification benefits that reduce reliance on any single domestic healthcare market.
The stock faces headwinds from a compressed valuation environment given the historical pattern of net losses extending through 2024, which suggests ongoing structural challenges in restoring sustainable earnings power; high levels of long-term debt at $1.27B combined with recent large debt repayments could constrain capital allocation options for strategic acquisitions or R&D expansion; and margin pressure from rising raw material costs and competitive pricing dynamics may limit the ability to pass on inflationary impacts to healthcare customers.
ICU Medical Inc. (ICUI) is a leading global manufacturer of disposable medical supplies and reusable sterilization equipment serving hospitals, surgical centers, and healthcare facilities worldwide. The company leverages its extensive distribution network to provide high-quality infection control products across the Americas, Europe, and Asia-Pacific markets. Its diverse portfolio includes advanced sterilization solutions, point-of-care testing devices, and essential patient care consumables that are critical for modern healthcare operations.
Despite a challenging year with net income turning positive at $0.7M after years of losses, the company generated strong operating cash flow of $179.8M reflecting efficient working capital management and robust underlying demand for its essential medical supplies. The balance sheet shows healthy liquidity with $308M in cash on hand, though substantial debt repayments of $302.8M suggest a strategic focus on deleveraging to improve financial flexibility. Revenue remained stable at $2.23B compared to recent highs, indicating resilience against broader healthcare spending pressures.
The global medical supplies industry is experiencing steady growth driven by aging populations, expanding healthcare infrastructure in emerging markets, and increasing adoption of advanced infection control protocols following recent pandemics; however, the sector faces headwinds from supply chain volatility, regulatory scrutiny on single-use plastics, and consolidation as larger corporations seek scale advantages; companies with strong distribution networks and proprietary reusable equipment portfolios are better positioned to navigate these structural shifts.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.28B | $2.26B | $2.38B | $2.23B |
| Cost of Revenue | $1.58B | $1.52B | $1.56B | $1.41B |
| Gross Profit | $697.8M | $739.9M | $824.8M | $822.0M |
| Operating Expenses | $740.7M | $717.0M | $781.8M | $779.2M |
| Operating Income | $-42.9M | $22.8M | $43.0M | $42.8M |
| R&D | $93.0M | $85.3M | $88.6M | $87.5M |
| G&A | $608.3M | $606.7M | $638.8M | $625.2M |
| Stock-Based Comp | $36.0M | $40.6M | $46.9M | $55.8M |
| D&A | $235.2M | $228.8M | $219.5M | $200.7M |
| Depreciation | $95.8M | $96.7M | $85.2M | $69.3M |
| Amortization | $139.4M | $132.1M | $134.3M | $131.4M |
| Other OpEx | $39.3M | $25.0M | $54.4M | $66.5M |
| Non-Operating Income | $-92.7M | $-159.8M | $-159.0M | $-38.5M |
| Interest Expense | $70.8M | $102.7M | $106.5M | $93.3M |
| Interest Income | $4.4M | $7.5M | $10.8M | $10.3M |
| Pre-Tax Income | $-135.6M | $-137.0M | $-116.0M | $4.4M |
| Income Tax | $-40.1M | $-48.6M | $51.7M | $2.4M |
| Continuing Ops | $-95.5M | $-88.3M | $-167.7M | $1.9M |
| Discontinued Ops | $21.2M | $58.7M | $50.0M | $-1.2M |
| Net Income | $-74.3M | $-29.7M | $-117.7M | $732.0K |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-74.3M | $-29.7M | $-117.7M | $732.0K |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.24B | $1.22B | $1.44B | $1.19B |
| Cash & Equivalents | $208.8M | — | — | — |
| Accounts Receivable | $221.7M | $161.6M | $182.8M | $180.5M |
| Inventory | $696.0M | $709.4M | $584.7M | $615.9M |
| Prepaid Expenses | $88.9M | $73.6M | $70.3M | $86.2M |
| Other Current Assets | $19.8M | $276.7M | $604.2M | $308.0M |
| Long-Term Assets | $3.28B | $3.16B | $2.76B | $2.86B |
| PP&E (Net) | $636.1M | $612.9M | $442.7M | $451.8M |
| Intangibles | $982.8M | $870.6M | $740.8M | $633.6M |
| Goodwill | $1.45B | $1.47B | $1.43B | $1.50B |
| Operating Leases | $74.9M | $69.9M | $53.3M | $54.5M |
| Other LT Assets | $134.3M | $128.2M | $89.3M | $88.8M |
| Total Assets | $4.52B | $4.38B | $4.20B | $4.05B |
| Current Liabilities | $494.6M | $481.8M | $556.2M | $498.9M |
| Accounts Payable | $215.9M | $150.0M | $148.0M | $154.4M |
| Current Debt | $29.7M | $51.0M | $51.0M | $18.8M |
| Current Leases | $18.2M | $20.2M | $15.7M | $13.8M |
| Deferred Revenue | $30.8M | $31.6M | $30.4M | $33.8M |
| Taxes Payable | $6.2M | $7.7M | $17.3M | $10.4M |
| Other Current Liab | $-49.0M | $-46.9M | $-13.1M | $-47.7M |
| Long-Term Liabilities | $1.93B | $1.77B | $1.68B | $1.43B |
| Long-Term Debt | $1.62B | $1.58B | $1.53B | $1.27B |
| LT Operating Leases | $60.9M | $53.0M | $40.8M | $44.0M |
| Other LT Liab | $188.5M | $96.8M | $65.7M | $83.3M |
| Total Liabilities | $2.43B | $2.26B | $2.24B | $1.93B |
| Shareholders' Equity | $2.09B | $2.12B | $1.97B | $2.12B |
| Retained Earnings | $837.5M | $807.8M | $690.2M | $690.9M |
| AOCI | $-81.0M | $-53.1M | $-139.4M | $-34.6M |
| Treasury Stock | $243.0K | $262.0K | $92.0K | $22.0K |
| Total L&E | $4.52B | $4.38B | $4.20B | $4.05B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-74.3M | $-29.7M | $-117.7M | $732.0K |
| Non-Cash Adjustments | $-190.1M | $283.7M | $220.8M | $172.8M |
| Working Capital Changes | $202.3M | $-87.8M | $100.9M | $6.3M |
| Cash from Operations | $-62.1M | $166.2M | $204.0M | $179.8M |
| Capital Expenditures | $90.3M | $83.9M | $79.4M | $88.0M |
| Cash from Investing | $-1.91B | $-87.9M | $-89.0M | $122.2M |
| Debt Repayments | $22.4M | $29.7M | $51.0M | $302.8M |
| Share Buybacks | $10.9M | $9.3M | $12.0M | $8.8M |
| Cash from Financing | $1.64B | $-36.0M | $-55.8M | $-311.5M |
| FX Effect | $-9.5M | $3.2M | $-4.9M | $8.8M |
| Net Change in Cash | $-344.0M | $45.4M | $54.3M | $-603.0K |
| Beginning Cash | $552.8M | $208.8M | $254.2M | $308.6M |
| Ending Cash | $208.8M | $254.2M | $308.6M | $308.0M |
The company operates primarily through its Reusable Medical Supplies segment which focuses on high-value sterilizers, washers, and autoclaves; the Disposable Medical Supplies segment covering infection control, respiratory therapy, and surgical consumables; and International Markets which serves healthcare providers in Europe, Latin America, and Asia with localized product offerings.
Significant exposure to foreign exchange rate fluctuations impacting international revenue translation; potential regulatory shifts in infection control standards affecting disposable product formulations; supply chain disruptions that could delay delivery of essential medical consumables; and intense competition from emerging low-cost manufacturers eroding gross margins on standardized products.
ICUI maintains a robust moat through its proprietary reusable equipment technology that creates recurring revenue streams via service contracts and supply agreements; an extensive global distribution footprint ensuring rapid product availability for critical hospital needs; and a diversified product portfolio that mitigates reliance on any single healthcare sub-sector or geographic region.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.